Novo Nordisk Stock Drops on Eli Lilly Oral Weight-Loss Drug Success, Downgrade
U.S.-listed shares of Novo Nordisk plunged 7% in intraday trading Thursday after rival Eli Lilly reported positive oral weight-loss drug news and BMO cut its rating for the Danish drug developer's stock.